 |
 | Home | Contact Us | FAQ | Search & Site Map | Link to Us |
 | Sign In | Join | Other 45 Sites in Network |
Medical Forum / Diseases and Disorders / Cancer / May 2008Colorectal cancer life expectancy
My father is 70 and he is fighting is second colorectal cancer. The first one was surgically removed 2-3 years ago, but a second tumor rapidly appeared. He has gone through radiotherapy and chemiotherapy for the past 18 months or so, and he has a tumor which doctors cannot remove because it is "too invasive" and the operation would likely kill him. Chemiotherapy has apparently reduced slightly the size of the tumor, but it still cannot be removed surgically. Doctors continue to provide him with "short" chemiotherapy sessions (6-8 weeks) with scans and blood samples in-between, but they never made any statement about a possible outlook. Sure, it is not a an exact science. Nevertheless I don't expect him to go through chemiotherapy for another 10 years. I tried to find statistics about the life expectancy of someone with a "non-removable" colon tumor (whatever what stage this is, we've never been told) but could not find anything on the subject. If anyone has links to point to or similar stories, please let me know. thanks. Paul > My father is 70 and he is fighting is second colorectal cancer. The > first one was surgically removed 2-3 years ago, but a second tumor [quoted text clipped - 15 lines] > > Paul For patients with a rectal cancer not treated surgically, about 1/3rd of patients are alive at 5 years. 2/3rds of those are alive with evidence of disease. If your father's cancer is recurrent disease, these figures do not apply, as median survival is about 18 months in those circumstances. Median is median, however. 50% of people do better, 50% worse. <paul_silverman@mail.com> kirjoitti Wed, 30 Apr 2008 23:29:51 +0300: > My father is 70 and he is fighting is second colorectal cancer. The > first one was surgically removed 2-3 years ago, but a second tumor [quoted text clipped - 13 lines] > been told) but could not find anything on the subject. If anyone has > links to point to or similar stories, please let me know. thanks. If I was you, I'd look into low dose naltrexone. This immunomodulator has helped some people with cancer, putting some in remission and extending expected survival for others. There is even a published case study of a patient with advanced pancreatic cancer who is still alive years after his diagnosis, even though he was only given a few months. There are some real advantage to this therapy: it is extremely safe and low on side effects - most people experience no side effects at all. Unlike most cancer treatments it doesn't adversely affect the quality of life; in fact it can have the opposite effect. It does not interact with any medications but narcotic painkillers (it cannot be used with opioids). It is inexpensive, costing about $20 a month. Any doctor can write a prescription. In case you're skeptical, which is a healthy attitude because there is a lot of quackery, please take a look at this list of scientific references I've gathered related to the subject: http://ldn.gehennom.org/tiede.html (the page is in Finnish, but the references are in English, there are no ads of any kind). Not all of them are about cancer, but there are dozens of studies that have shown that the mode of action is entirely plausible. Some of them are specifically about colon cancer. The most interesting paper would probably be this one: Hytrek SD, McLaughlin PJ, Lang CM et al. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett. 1996 Mar 29;101(2):159-64. PMID: 8620464. You can find more information at http://www.lowdosenaltrexone.org  Signature%. _ /) That's why I didn't kill myself sooner, the pressure `%-('`._/ ) _ of spelling mistakes. -"5 Suicide Notes" by Saracen Tate `\ \ `'/ Maija Haavisto * DiamonDie@IRCnet * http://www.fiikus.net `.___.'mh My CFS/ME/FM book: http://www.brokenmarionettebook.com > <paul_silverman@mail.com> kirjoitti Wed, 30 Apr 2008 23:29:51 +0300: > [quoted text clipped - 16 lines] > PMID: 8620464. You can find more information at > http://www.lowdosenaltrexone.org Don't believe everything you read. If it's been around and successful with cancer, since 1996, there would be clinical trials and there are none for naltrexone and cancer. 138 for oother diseases and/or conditions but NONE for cancer. Save your money. There are multiple spammerss, on various health newsgroups, trying to "sell" people on it. Suspicions they're sales people. (trying to make money off desperate cancer patients). J 1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system. Neuro Endocrinol Lett. 2002 Aug;23(4):341-4. PMID: 12195238 [PubMed - indexed for MEDLINE]2: Related Articles, LinksLissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett. 2002 Jun;23(3):255-8. PMID: 12080288 [PubMed - indexed for MEDLINE]3: Related Articles, LinksLissoni P, Meregalli S, Fossati V, Barni S, Tancini G, Barigozzi P, Frigerio F. Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy. Tumori. 1993 Jun 30;79(3):198-201. PMID: 8236504 [PubMed - indexed > > <paul_silver...@mail.com> kirjoitti Wed, 30 Apr 2008 23:29:51 +0300: > [quoted text clipped - 28 lines] > > - Show quoted text - > 1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov > V, Laudon M, Conti A, Maestroni G. [quoted text clipped - 19 lines] > Tumori. 1993 Jun 30;79(3):198-201. > PMID: 8236504 [PubMed - indexed And how was life expectancy affected, if at all? J A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. Division of Radiation Oncology, S. Gerardo Hospital, Monza, Milan, Italy. OBJECTIVES: Recent advances in knowledge of Psychoneuroimmunology have shown that several neuroactive substances, including neurohormones and neuropeptides, may exert immunomodulatory effects. However, despite the great variety of potential neuroimmune interactions, at present we may recognize two major neuroendocrine systems exerting a physiological neuroimmunomodulatory function, consisting of the pineal gland and the brain opioid system, provided by immunostimulatory and immunosuppressive effects, respectively. Recent in human studies have demonstrated the possibility to amplify the biological activity of IL-2, the major anticancer cytokine, by pineal indoles. MATERIALS & METHODS: The present study was carried out to draw some preliminary in human results on the possible immunomodulatory effects of the inhibition of the brain opioid activity by a long-acting opioid antagonist, naltrexone (NTX). The study was performed in 10 metastatic renal cell cancer patients, who had progressed on a previous immunotherapeutic cycle with IL-2 alone. Patients were treated with the same doses of IL-2 (6 million lU/day subcutaneously for 6 days/ week for 4 weeks) plus an oral administration of NTX at a dose of 100 mg every 2 days. RESULTS: The clinical response consisted of a partial response in 1 and a stable disease in 5 patients, whereas the other 4 patients progressed. Therefore, the percent of non-progressive disease was 6/10 (60%). Moreover, mean lymphocyte increase achieved during IL-2 plus NTX was significantly higher (P<0.05) than that obtained during the previous treatment with IL-2 alone. CONCLUSIONS: This study shows that a blockade of the brain opioid system, which plays a physiological immunosuppressive role, may improve the anticancer effects of IL-2 in humans. PMID: 12080288 [PubMed - indexed for MEDLINE] > > 1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov > > V, Laudon M, Conti A, Maestroni G. [quoted text clipped - 24 lines] > > - Show quoted text - > A new neuroimmunotherapeutic strategy of subcutaneous low-dose > interleukin-2 plus the long-acting opioid antagonist naltrexone in [quoted text clipped - 32 lines] > > PMID: 12080288 [PubMed - indexed for MEDLINE] Which proves that cancer in each person can be variable for a number of reasons. Nothing more. J |
Reply to this Message |
 Sign In
 Join
 My Latest Posts My Monitored Threads My Blog My Photo Gallery My Profile My Homepage Start New Thread Enable EMail Alerts Rate this Thread
|
©2008 Advenet LLC Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.